At last - Alzheimer's lobbying pays off

I mentioned in my first lecture that I was heavily involved with a public and private lobbying campaign across the BBC and national press, but focussing on the Daily Mail. I was working on behalf of one pharmaceutical company, but in conjunction with other pharma companies, and the Alzheimer's Society, to change the National Institute of Clinical Excellence (NICE) decision to prohibit prescribing of Alzheimer's drugs until symptoms were advanced beyond the basic stages. Doctors, carers, patients and the clinical evidence argued that earlier prescribing would delay symptoms longer and allow carers and patients to come to term with the disease and make arrangements for their futures. Such lobbying has lasted 5 years.

Today, NICE finally revised their decision on this...